Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
40366350 2025 A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. Molecular cancer therapeutics Likely relevant The study tests the bispecific antibody PF-07260437, palbociclib, fulvestrant, and anti-PD-1 in breast cancer cell lines and animal models, measuring T-cell numbers, activation, and intratumoral CD8 T cells. PF-07260437; palbociclib; fulvestrant; anti-PD-1 Mixed breast cancer PF-07260437 0/0/0; palbociclib 0/2/0; fulvestrant 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
40369063 2025 STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity. Nature Likely relevant The study experimentally tests STAT3 PROTAC degraders (SD-36 and SD-2301) in mice and measures effects on dendritic cell function and T cell immunity. SD-36; SD-2301 Animal advanced tumours SD-36 0/0/0; SD-2301 0/0/0 Awaiting curator check
40424822 2025 Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Likely relevant The study tests CD39/CD73 inhibitors and anti-PD-L1 immunotherapy in a murine bladder cancer model and measures circulating T cells and the neutrophil-to-lymphocyte ratio. anti-PD-L1; CD39 inhibitors; CD73 inhibitors Animal bladder cancer anti-PD-L1 0/15/0; CD39 inhibitors 0/0/0; CD73 inhibitors 0/0/0 Awaiting curator check
40433989 2025 Exosomal CMTM4 Induces Immunosuppressive Macrophages to Promote Ovarian Cancer Progression and Attenuate Anti-PD-1 Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study evaluates eltrombopag as a CMTM4 inhibitor combined with PD-1 blockade in vivo, assessing macrophage polarization and immune microenvironment changes. eltrombopag; anti-PD-1 Animal ovarian cancer eltrombopag 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
40439109 2025 Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer communications (London, England) Likely relevant The study tests anti-PD-1 antibodies and lipid inhibitors in vivo and evaluates their effects on immune evasion, PD-L1 levels, and the tumor microenvironment. anti-PD-1; PCSK9-neutralizing antibodies; lipid inhibitors Mixed pancreatic ductal adenocarcinoma anti-PD-1 14/36/0; PCSK9-neutralizing antibodies 0/0/0; lipid inhibitors 0/0/0 Awaiting curator check
40439143 2025 Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma. Oncoimmunology Likely relevant The study tests anti-PD-L1 and anti-VEGFR2 in a mouse model of pleural mesothelioma and analyzes tumor-infiltrating immune cells and T cell exhaustion. anti-PD-L1; anti-VEGFR2 Animal pleural mesothelioma anti-PD-L1 0/15/0; anti-VEGFR2 0/0/0 Awaiting curator check
40461940 2025 Reprogramming Tumor-Associated Macrophage by Ornithine Decarboxylase Inhibitor and Immune Checkpoint for Orthotopic Glioblastoma Photothermal Immunotherapy. ACS applied materials & interfaces Likely relevant The study tests DFMO, aPD-L1, and ICG in an orthotopic glioma mouse model and measures TAM repolarization, phagocytic activity, and immunogenic cell death. difluoromethylornithine; aPD-L1; Indocyanine Green Animal glioblastoma difluoromethylornithine 0/0/0; aPD-L1 0/0/0; Indocyanine Green 1/2/0 Awaiting curator check
40465005 2025 Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models. Cancer immunology, immunotherapy : CII Likely relevant The study tests an oncolytic adenovirus combined with chemotherapy and immune checkpoint inhibitors in ex vivo tumor samples and hamster models, measuring PD-L1, cytokines, and CD8+ T cell expansion. Ad5/3-E2F-d24-vIL2; chemotherapy; immune checkpoint inhibitor Mixed pancreatic ductal adenocarcinoma Ad5/3-E2F-d24-vIL2 0/0/0; chemotherapy 2/0/3; immune checkpoint inhibitor 0/0/0 Awaiting curator check
40522918 2025 Estrogens determine the efficacy of cancer immunotherapy in obese males with melanoma. JCI insight Likely relevant The study investigates the impact of obesity, estrogen levels, and letrozole administration on anti-PD-1 efficacy and CD8+ T cell/dendritic cell functions in mice and human melanoma patients. immune checkpoint inhibitors (ICI); anti-PD-1; letrozole Mixed melanoma immune checkpoint inhibitors (ICI) 0/0/0; anti-PD-1 14/36/0; letrozole 0/0/0 Awaiting curator check
40591413 2025 Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. The Journal of clinical investigation Likely relevant The study investigates LAIR1 inhibition via antibody blockade and CAR T cells in tumor models and measures changes in CD8 memory T cells and macrophage phenotypes. anti-Lair1 antibody; 3-in-1 CAR T cells Animal cancer (tumor models) anti-Lair1 antibody 0/0/0; 3-in-1 CAR T cells 0/0/0 Awaiting curator check
40605065 2025 Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy. Journal of experimental & clinical cancer research : CR Likely relevant The study tests an anti-PD-1 antibody combined with the NMT1 inhibitor PCLX-001 in HNSCC xenograft mice, measuring PD-L1 membrane localization and immune suppression. anti-PD-1 antibody; PCLX-001 Animal head and neck squamous cell carcinoma anti-PD-1 antibody 0/2/0; PCLX-001 0/0/0 Awaiting curator check
40610636 2025 Impaired autophagy by cepharanthine induces immunogenic cell death and enhances anti-PD-1 response in MSS-type colorectal cancer. Oncogene Likely relevant Examines the immunogenic cell death and immune responses induced by cepharanthine and anti-PD-1 therapy in CRC models. cepharanthine; anti-PD-1 Animal colorectal cancer cepharanthine 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
40646287 2025 Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy. British journal of cancer Likely relevant The study experimentally tests the ribosome biogenesis inhibitor CX-5461 in in vivo models and human samples, measuring its immunomodulatory effects on immune cell cytotoxicity, macrophage reprogramming, and immune checkpoint expression. CX-5461 Mixed cancer CX-5461 2/0/0 Awaiting curator check
40665335 2025 Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer. Journal of experimental & clinical cancer research : CR Likely relevant The study tests ENO1 knockdown/inhibition alongside anti-PD-L1 immunotherapy in models and clinical samples, measuring CD8+ T cell infiltration and macrophage polarization. anti-PD-L1 Mixed bladder cancer anti-PD-L1 0/15/0 Awaiting curator check
40702186 2025 NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature Likely relevant The study tests a small molecule NNMT inhibitor in murine models and measures its impact on MDSCs and CD8+ T cell activation. NNMT inhibitor Animal ovarian cancer, breast cancer, colon tumour NNMT inhibitor 0/0/0 Awaiting curator check
40745160 2025 Mogat1 drives metabolic adaptations to evade immune surveillance. Nature communications Likely relevant The study evaluates the effect of PD-1 blockade in combination with genetic inhibition of Mogat1 in tumor-bearing mice and measures T-cell infiltration. PD-1 blockade Animal solid tumors PD-1 blockade 0/0/0 Awaiting curator check
40774370 2025 Nanoparticle-induced excessive mitophagy combined with immune checkpoint blockade for enhanced cancer immunotherapy. Acta biomaterialia Likely relevant The study uses a therapeutic nanoplatform to induce mitophagy and silence PD-L1 in breast cancer models, evaluating CD8+ T cell activity and immunosuppressive cell infiltration. CCCP; siRNA against PD-L1 Animal breast cancer CCCP 0/0/0; siRNA against PD-L1 0/0/0 Awaiting curator check
40801643 2025 Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer. Cells Likely relevant The study evaluates surgical resection after chemotherapy or anti-PD-1 therapy in patients with gastric cancer and analyzes the immune status (HLA class I and MHC class II expression) of the tumor microenvironment. anti-PD-1 therapy; chemotherapy Patient gastric/gastroesophageal junction cancer anti-PD-1 therapy 0/0/0; chemotherapy 2/0/3 Awaiting curator check
40810617 2025 Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder-Metastasized Tumors. Advanced materials (Deerfield Beach, Fla.) Likely relevant The study tests a nanozyme-based platform combined with PD-L1 nanobody in a bladder cancer model and measures immunogenic cell death and immune activation. RePd nanozyme; PD-L1 nanobody; immune-checkpoint inhibitors Animal bladder cancer RePd nanozyme 0/0/0; PD-L1 nanobody 0/0/0; immune-checkpoint inhibitors 0/0/0 Awaiting curator check
40816293 2025 DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. Cancer cell Likely relevant Tests DNASE1L3 injection alongside anti-PD-(L)1 therapy in murine tumor models, measuring CD8+ T cell infiltration and exhaustion. anti-PD-(L)1 Animal cancer (general) anti-PD-(L)1 0/0/0 Awaiting curator check
40828008 2025 Programmable immunoprobiotics orchestrate antitumor immune response with Pin1 inhibition for pancreatic cancer treatment. Proceedings of the National Academy of Sciences of the United States of America Likely relevant The study tests a Pin1 inhibitor and anti-PD-L1 delivery system in orthotopic mouse models and assesses immune cell infiltration and CD8+ T cell immunity. API-1; anti-PD-L1 nanobodies Animal pancreatic ductal adenocarcinoma API-1 0/0/0; anti-PD-L1 nanobodies 0/0/0 Awaiting curator check
40851062 2025 The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy. BMC cancer Likely relevant The study investigates the association of immune cell infiltrates (CD4, CD8, CD68, FoxP3, PD-L1) with patient response to anti-PD-1 immunotherapy (sintilimab) combined with platinum-based chemotherapy. sintilimab; platinum-based chemotherapy Patient Gastric or Gastroesophageal Junction (G/GEJ) cancer sintilimab 0/0/1; platinum-based chemotherapy 0/0/0 Awaiting curator check
40886775 2025 Polymeric-based neoantigen nanovaccine synergizes with PD-1/PD-L1 modulators, reprogramming the melanoma microenvironment. Journal of controlled release : official journal of the Controlled Release Society Likely relevant The study experimentally tests a polymeric nanovaccine combined with PD-1/PD-L1 pathway modulators in a mouse melanoma model and measures T-cell activation, infiltration, and immunosuppressive cell populations. mannose-grafted PLGA nanovaccine; anti-PD-L1 monoclonal antibody; SM56 Animal melanoma mannose-grafted PLGA nanovaccine 0/0/0; anti-PD-L1 monoclonal antibody 0/0/0; SM56 0/0/0 Awaiting curator check
40907793 2025 Polymer-based chemo-immunotherapy: Combining immunogenic cell death induction and PD-L1 blockade enhances antitumor immunity in melanoma. Journal of controlled release : official journal of the Controlled Release Society Likely relevant Tests a polymer-based chemo-immunotherapy conjugate (KT-1/epirubicin and MPPA) in melanoma models and measures multiple immune readouts. KT-1; MPPA; epirubicin Animal melanoma KT-1 0/0/0; MPPA 0/0/0; epirubicin 0/0/0 Awaiting curator check
40909279 2025 SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8+ T cells to immune checkpoint blockade. Frontiers in immunology Likely relevant The study tests the combination of SLAMF7 activation with PD-1/PD-L1 immune checkpoint blockade in human T cells, measuring cytokine release and cytotoxic potential. PD-1/PD-L1 immune checkpoint blockade Cell line head and neck squamous cell carcinoma (HNSCC) PD-1/PD-L1 immune checkpoint blockade 0/0/0 Awaiting curator check
← Previous Page 5 of 15 Next →